Skip to main content
Erschienen in: Gastro-News 6/2019

04.12.2019 | Chronisch-entzündliche Darmerkrankungen | aktuell

DDW-Kongress in San Diego CA — Teil 3

UpToDate bei Kolon, Mikrobiom und CED

verfasst von: PD Dr. med. Birgit Terjung, Prof. Dr. med. Dr. rer. biol. hum. Manfred Gross

Erschienen in: Gastro-News | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Auf dem amerikanischen Gastroenterologie-Kongress (DDW, Digestive Disease Week), der 2019 in San Diego CA stattfand, erfuhren mehr als 14.000 Teilnehmer alles über aktuelle Standards, Neuigkeiten und wissenschaftliche Erkenntnisse zu Kolon, Mikrobiom und chronisch entzündlichen Darmerkrankungen. In einer Serie von Artikeln werden in GASTRO NEWS die Inhalte der wichtigsten Vorträge und Abstracts präsentiert.
Literatur
2.
Zurück zum Zitat Ma W et al. Gastroenterology 2019;156(6) Suppl 1: Abstract Tu1595 Ma W et al. Gastroenterology 2019;156(6) Suppl 1: Abstract Tu1595
3.
Zurück zum Zitat Nguyen LH et al. Gastroenterology 2019;156(6) Suppl 1: Abstract Tu1875 Nguyen LH et al. Gastroenterology 2019;156(6) Suppl 1: Abstract Tu1875
4.
Zurück zum Zitat Taneja SL et al. Gastroenterology 2019;156(6) Suppl 1: OP 838 Taneja SL et al. Gastroenterology 2019;156(6) Suppl 1: OP 838
5.
Zurück zum Zitat Ciezki KJ et al. Gastroenterology 2019;156(6) Suppl 1: Abstract Mo1627 Ciezki KJ et al. Gastroenterology 2019;156(6) Suppl 1: Abstract Mo1627
6.
Zurück zum Zitat Chang SH et al. Gastroenterology 2019;156(6) Suppl1: Abstract Mo1717 Chang SH et al. Gastroenterology 2019;156(6) Suppl1: Abstract Mo1717
7.
Zurück zum Zitat Fritscher-Ravens A et al. Gastroenterology 2019;156(6) Suppl1: OP946 Fritscher-Ravens A et al. Gastroenterology 2019;156(6) Suppl1: OP946
8.
Zurück zum Zitat Heyde S et al. Gastroenterology 2019, 156(6) Suppl1: Abstract Su1625 Heyde S et al. Gastroenterology 2019, 156(6) Suppl1: Abstract Su1625
9.
Zurück zum Zitat Garcia-Zermeno KR et al. Gastroenterology 2019;156(6) Suppl1: Abstract Sa1658 Garcia-Zermeno KR et al. Gastroenterology 2019;156(6) Suppl1: Abstract Sa1658
10.
Zurück zum Zitat Leite G JH et al. Analysis of the small intestinal microbiome reveals marked differences from stool microbiome in a large scale human cohort: redefining the „gut microbiome.“ Gastroenterology 2019;156(6) Suppl 1: Abstract Sa1911 Leite G JH et al. Analysis of the small intestinal microbiome reveals marked differences from stool microbiome in a large scale human cohort: redefining the „gut microbiome.“ Gastroenterology 2019;156(6) Suppl 1: Abstract Sa1911
11.
Zurück zum Zitat Haydek JP et al. Differences among luminal and mucosal microbiota among fecal microbiota transplant recipients. Gastroenterology 2019;156(6) Suppl 1: Abstract Tu1863 Haydek JP et al. Differences among luminal and mucosal microbiota among fecal microbiota transplant recipients. Gastroenterology 2019;156(6) Suppl 1: Abstract Tu1863
12.
Zurück zum Zitat Villanueva-Millan M et al. Deep sequencing of the entire human small intestine: a comparison to stool microbiome in the REIMAGINE study. Gastroenterology 2019;156(6) Suppl1: Abstract Sa1909 Villanueva-Millan M et al. Deep sequencing of the entire human small intestine: a comparison to stool microbiome in the REIMAGINE study. Gastroenterology 2019;156(6) Suppl1: Abstract Sa1909
13.
Zurück zum Zitat Jin G et al. Intestine microbiome aspiration (IMBA) capsule: a new autonomous and minimally-invasive device for whole gut microbiome sampling and mapping. Gastroenterology 2019;156(6) Suppl1: OP977 Jin G et al. Intestine microbiome aspiration (IMBA) capsule: a new autonomous and minimally-invasive device for whole gut microbiome sampling and mapping. Gastroenterology 2019;156(6) Suppl1: OP977
14.
Zurück zum Zitat Stallmach A et al. Long-term multidonor fecal microbiota transfer (FMT) by oral capsules for active ulcerative colitis. Gastroenterology 2019;156(6) Suppl1: OP1129 Stallmach A et al. Long-term multidonor fecal microbiota transfer (FMT) by oral capsules for active ulcerative colitis. Gastroenterology 2019;156(6) Suppl1: OP1129
15.
Zurück zum Zitat Ott SJ et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. Gastroenterology 2017; 152(4):799–811CrossRef Ott SJ et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection. Gastroenterology 2017; 152(4):799–811CrossRef
16.
Zurück zum Zitat Phillips L et al. Marked Alterations in the viral genome in patients with recurrent Clostridium difficile infection before and after fecal microbiota transplant. Gastroenterology 2019;156(6) Suppl 1: OP426 Phillips L et al. Marked Alterations in the viral genome in patients with recurrent Clostridium difficile infection before and after fecal microbiota transplant. Gastroenterology 2019;156(6) Suppl 1: OP426
18.
Zurück zum Zitat Cammarota G, Ianiro G, Tilg H et al. (2017) European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017; 66: 569–580CrossRef Cammarota G, Ianiro G, Tilg H et al. (2017) European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017; 66: 569–580CrossRef
19.
Zurück zum Zitat Borren N et al. Impact of biologic therapy on resolution of fatigue symptoms in patients with active inflammatory bowel disease: a prospective cohort study. Gastroenterology 2019; 156(6): Sa1861 Borren N et al. Impact of biologic therapy on resolution of fatigue symptoms in patients with active inflammatory bowel disease: a prospective cohort study. Gastroenterology 2019; 156(6): Sa1861
20.
Zurück zum Zitat Borren N et al. Gut microbial dysbiosis contributes to fatigue in patients with quiescent inflammatory bowel diseases. Gastroenterology 2019; 156(6) Suppl 1: OP146. Borren N et al. Gut microbial dysbiosis contributes to fatigue in patients with quiescent inflammatory bowel diseases. Gastroenterology 2019; 156(6) Suppl 1: OP146.
21.
Zurück zum Zitat Narula N et al. Risk of infectious complications from medical therapies in post-surgical patients. Gastroenterology 2019; 156(6) Suppl1: OP 640 Narula N et al. Risk of infectious complications from medical therapies in post-surgical patients. Gastroenterology 2019; 156(6) Suppl1: OP 640
22.
Zurück zum Zitat Cohen BL et al. Anti-tumor necrosis factor therapy is not associated with postoperative infection: results from prospective cohort of ulcerative colitis and Crohn’s disease patients undergoing surgery to identify risk factors for post-operative infection (PUCCINI). Gastroenterology 2019; 156(6) Suppl1: OP 415a Cohen BL et al. Anti-tumor necrosis factor therapy is not associated with postoperative infection: results from prospective cohort of ulcerative colitis and Crohn’s disease patients undergoing surgery to identify risk factors for post-operative infection (PUCCINI). Gastroenterology 2019; 156(6) Suppl1: OP 415a
23.
Zurück zum Zitat Sands B et al. Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: week 44 results from UNIFI. Gastroenterology 2019; 156(6) Suppl1: OP 833 Sands B et al. Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: week 44 results from UNIFI. Gastroenterology 2019; 156(6) Suppl1: OP 833
24.
Zurück zum Zitat Sands B et al. Efficacy in biologic failure and nonbiologic failure populations in a phase 3-study of ustekinumab in moderate-severe ulcerative colitis: UNIFI. Gastroenterology 2019; 156(6) Suppl1: OP 833a Sands B et al. Efficacy in biologic failure and nonbiologic failure populations in a phase 3-study of ustekinumab in moderate-severe ulcerative colitis: UNIFI. Gastroenterology 2019; 156(6) Suppl1: OP 833a
25.
Zurück zum Zitat Sands B et al. Characterization of patients with delayed response to ustekinumab for Crohn’s disease. Gastroenterology 2019; 156(6) Suppl1: Tu 1725 Sands B et al. Characterization of patients with delayed response to ustekinumab for Crohn’s disease. Gastroenterology 2019; 156(6) Suppl1: Tu 1725
26.
Zurück zum Zitat Sands B et al. Vedolizumab shows superior efficacy versus adalimumab: results of VARSITY - the first head-to-head Study of biologic therapy for moderate to severe ulcerative colitis. Gastroenterology 2019; 156(6) Suppl1: LB Abstract 416a Sands B et al. Vedolizumab shows superior efficacy versus adalimumab: results of VARSITY - the first head-to-head Study of biologic therapy for moderate to severe ulcerative colitis. Gastroenterology 2019; 156(6) Suppl1: LB Abstract 416a
27.
Zurück zum Zitat Dubinky M et al. Measuring the mediating effects of tofacitinib on health status in ulcerative colitis: data from the OCTAVE program. Gastroenterology 2019; 156(6) Suppl1: Sa 1872 Dubinky M et al. Measuring the mediating effects of tofacitinib on health status in ulcerative colitis: data from the OCTAVE program. Gastroenterology 2019; 156(6) Suppl1: Sa 1872
28.
Zurück zum Zitat Chiorean MV et al. Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies. Gastroenterology 2019; 156(6) Suppl1: OP 798CrossRef Chiorean MV et al. Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies. Gastroenterology 2019; 156(6) Suppl1: OP 798CrossRef
29.
Zurück zum Zitat Hanes L et al. Gastroenterology 2019; 156(6) Suppl1: OP179 Hanes L et al. Gastroenterology 2019; 156(6) Suppl1: OP179
31.
Zurück zum Zitat Sugimoto K et al. Highly bioavailable curcumin (Theracurmin) for Crohn’s disease: randomized, multicenter, double-blind, placebo-controlled trial. Gastroenterology 2019; 156(6) Suppl1: Abstract Tu1716 Sugimoto K et al. Highly bioavailable curcumin (Theracurmin) for Crohn’s disease: randomized, multicenter, double-blind, placebo-controlled trial. Gastroenterology 2019; 156(6) Suppl1: Abstract Tu1716
32.
Zurück zum Zitat Chandan S et al. Curcumin use in ulcerative colitis: is it ready for prime time? A systematic review and metaanalysis of clinical trials. Gastroenterology 2019; 156(6) Suppl1: Abstrac Su1871CrossRef Chandan S et al. Curcumin use in ulcerative colitis: is it ready for prime time? A systematic review and metaanalysis of clinical trials. Gastroenterology 2019; 156(6) Suppl1: Abstrac Su1871CrossRef
Zurück zum Zitat Digestive Disease Week (DDW) 18. – 21. Mai 2019 San Diego CA, USA Digestive Disease Week (DDW) 18. – 21. Mai 2019 San Diego CA, USA
Metadaten
Titel
DDW-Kongress in San Diego CA — Teil 3
UpToDate bei Kolon, Mikrobiom und CED
verfasst von
PD Dr. med. Birgit Terjung
Prof. Dr. med. Dr. rer. biol. hum. Manfred Gross
Publikationsdatum
04.12.2019
Verlag
Springer Medizin
Erschienen in
Gastro-News / Ausgabe 6/2019
Print ISSN: 1869-1005
Elektronische ISSN: 2520-8667
DOI
https://doi.org/10.1007/s15036-019-0698-x

Weitere Artikel der Ausgabe 6/2019

Gastro-News 6/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.